- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04345952
Calm for Cancer Patients Receiving Chemotherapy
Can a Mindfulness Meditation App Reduce Emotional Distress in Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chemotherapy is a common treatment modality among colorectal cancer patients. Despite improvements in survival among those receiving chemotherapy, patients often experience side effects including pain, nausea, vomiting, changes in appetite and weight, fatigue, depressed mood, and reduced quality of life. Colorectal cancer patients undergoing chemotherapy also experience acute elevation in psychological distress (e.g., anxiety, stress). Worldwide, as many as 40% of cancer patients currently report using complementary and alternative medicine (CAM) for the management of their diagnosis and treatment-related side effects. Evidence to support the efficacy of various CAM approaches is still in its infancy, and further research is warranted.
Mindfulness-based strategies, a popular CAM approach among cancer patients, may have unique benefits for addressing both treatment-related side effects as well as the management of acute levels of psychological distress experienced while undergoing chemotherapy. Preliminary evidence supports the benefits of meditation, relaxing sounds, and progressive muscle relaxation for the reduction of distress and state anxiety as well as the improvement of neuroendocrine responses, indicative of improved stress response, among cancer patients undergoing chemotherapy. Additionally, meditation has been shown to improve distress, cognitive function, mental health, quality of life, and chemotherapy-related neurotoxicity symptoms among cancer patients that had undergone chemotherapy treatment. Despite preliminary evidence to support mindfulness-based strategies to help cancer patients undergoing chemotherapy, further research is needed to determine their efficacy.
Smartphone applications (apps) are a unique mode of delivering mindfulness-based strategies to cancer patients and may help make CAM more accessible to cancer patients reporting barriers to participation in in-person interventions (e.g., pain, fatigue, transportation, scheduling difficulties, etc.). Additionally, smartphone apps are a way of providing mindfulness-based strategies to patients while undergoing chemotherapy without the need of specialized personnel to lead mindfulness-based sessions for patients in the clinic. Smartphone accessibility is becoming more ubiquitous, with nearly three quarters of cancer patients reporting access to a mobile smartphone. To our knowledge there have been no studies that have tested the effects of meditation delivered specifically via a smartphone app to cancer patients undergoing chemotherapy (one study used an iPad). The investigators have previously demonstrated the feasibility and preliminary effects of delivering four weeks of smartphone-based meditation (via the Calm app) to hematological cancer patients to improve symptom burden. However, these patients were not undergoing chemotherapy. A meditation app such as Calm could be used to deliver mindfulness-based strategies to cancer patients undergoing chemotherapy while in clinic and outside of clinic for the management of acute psychological distress and chemotherapy-related side effects.
The Calm app has over 2 million paying users and 65 million downloads, and was named Apple's "App of the Year" in 2017.9,10 The Calm app was developed based on tenets of mindfulness and cognitive behavioral therapy, and provides its users with a range of mindfulness-based options to choose from, including meditations, Sleep Stories, and Soundscapes. In the proposed study, the investigators will investigate the use of Calm among a small sample of colorectal cancer patients (N=30; n=15 per group) who are beginning adjuvant chemotherapy within 12-weeks post-surgery as compared to a usual care control group to determine its effects on acute psychological distress within a single chemotherapy session as well as chemotherapy-related side effects.
STUDY OBJECTIVES
Objective 1: Investigate the effects of using a meditation app to reduce psychological distress (measured using the Distress Thermometer), across multiple chemotherapy sessions (n=15) among colorectal cancer patients as compared to usual control (n=15).
The primary hypothesis for this objective is that those using a meditation app will experience a reduction in psychological distress from beginning to end of each chemotherapy session as compared to usual care.
Objective 2: Investigate the effects of using a meditation app on chemotherapy toxicity and tolerability (measured using patient medical records; dose reduction/modification, dose delays, # of cycles completed, hospitalization, cytopenias, etc.), fatigue (measured using the Brief Fatigue Inventory), and quality of life (measured using the General Version of the Functional Assessment of Cancer and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) among colorectal cancer patients during a chemotherapy treatment cycle (i.e., two-three week cycle between the sessions) as compared to a usual care control group.
The primary hypothesis for this objective is that those using the meditation app will experience less severe chemotherapy toxicity, greater chemotherapy tolerability, less fatigue, and greater quality of life as compared to the usual care control group.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Texas
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have a colorectal cancer diagnosis and waiting the beginning of adjuvant chemotherapy treatment at the Mays Cancer Center University of Texas (UT) Health San Antonio
- Own a mobile smartphone (iPhone with iOS 9.0 or later or an Android 4.1 or later)
- Willing to download a mobile app
- Able to read and understand English or Spanish
- Aged 18 years or older
- Willing to be randomized to one of two groups
Exclusion Criteria:
- Meditation or meditative movement practice (i.e., yoga, tai chi, qigong) of greater than or equal to 60 min/month in the past six months
- Use of any consumer-based meditation app
- Reside outside of the united states
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Calm Meditation
Participants in the Calm group will be asked to use the Calm app ad libitum during their time spent receiving chemotherapy at the Mays Cancer Center (~2 hours) and while at home between treatment cycles ad libitum.
Participation will be measured during the entire intervention using internal tracking systems within the app (i.e., # of times logged in, type of meditation accessed, time spent meditating, date and time of meditation accessed).
This data will be provided to us through data coordinator of the app.
|
The Calm Meditation Mobile App will be used to deliver the meditation intervention to study participants.
The Calm app is downloaded onto the participant's smartphone.
|
No Intervention: Usual Care
The usual care control group will not be offered anything to listen to during their chemotherapy treatment cycles or when they are between chemotherapy treatment cycles.
They will receive their treatment as intended without any additional intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Distress
Time Frame: 6-month average change from baseline (beginning of chemotherapy treatment session) to post-treatment (end of chemotherapy treatment session)
|
Distress will be measured with the Distress Thermometer at the beginning and end of each chemotherapy treatment session over the course of the approximate 6-month study duration.
The Distress Thermometer is a 10-point visual analog scale and a higher score indicates greater distress.
|
6-month average change from baseline (beginning of chemotherapy treatment session) to post-treatment (end of chemotherapy treatment session)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chemotherapy toxicity and tolerability
Time Frame: Post-intervention (month 6)
|
Chemotherapy toxicity and tolerability will be assessed through patient medical records by pulling the following variables from their record: dose reduction/modification, dose delays, # of cycles completed, hospitalization, cytopenias
|
Post-intervention (month 6)
|
Change in Fatigue
Time Frame: Change from baseline (week 0) to post-intervention (month 6)
|
Fatigue will be measured with the Brief Fatigue Inventory (BFI).
The score on the BFI ranges from 0-90 with a higher score indicating a higher amount of fatigue being measured.
|
Change from baseline (week 0) to post-intervention (month 6)
|
Change in Cancer Treatment-Related Quality of Life
Time Frame: Change from baseline (week 0) to post-intervention (month 6)
|
Cancer Treatment-Related Quality of Life will be measured with the General Version of the Functional Assessment of Cancer.
The Scale is scored on a 0-100 normalized scale with a higher score indicating a higher quality of life.
|
Change from baseline (week 0) to post-intervention (month 6)
|
Change in Cancer Health-Related Quality of Life
Time Frame: Change from baseline (week 0) to post-intervention (month 6)
|
Cancer Health-Related Quality of Life will be measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
The scale scoring ranges from 0-100 with a higher score indicating a higher quality of life.
|
Change from baseline (week 0) to post-intervention (month 6)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ruben Mesa, Mays Cancer Center at UT Health San Antonio MD Anderson
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CTMS# 20-0117
- HSC20200636H (Other Identifier: UT Health Science Center San Antonio IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer Colorectal
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on Calm Meditation Mobile App
-
Arizona State UniversityThe University of Texas Health Science Center at San AntonioCompleted
-
University of ArizonaCompletedAnxiety | Sleep Disturbance | Perceived StressUnited States
-
University of ArizonaUnknownPTSD | Burnout | Anxiety | Sleep Disturbance | Perceived StressUnited States
-
Arizona State UniversityCompletedMyeloproliferative NeoplasmUnited States
-
Calm.com, Inc.The University of Texas Health Science Center at San Antonio; Arizona State...Completed
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Completed
-
Kaiser PermanenteAmerican Cancer Society, Inc.CompletedCancer | Distress | Chemotherapy EffectUnited States
-
University of WashingtonNational Institute of Mental Health (NIMH)CompletedDepression | Anxiety | Emotional RegulationUnited States
-
Arizona State UniversityCompletedMeditation | Control GroupUnited States
-
Calm.com, Inc.TerminatedPregnancy RelatedUnited States